TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has shared an announcement.
Hemogenyx Pharmaceuticals has been invited to present at the DCNY Summit, a prestigious event that connects policymakers, investors, and corporate leaders, offering a platform to showcase their clinical progress and pipeline, including a Phase I trial for CAR-T cell therapy targeting acute myeloid leukemia. This opportunity is expected to enhance Hemogenyx’s visibility among influential stakeholders and potentially secure growth capital, thereby advancing its mission to transform cancer treatment.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, leveraging distinct product candidates and platform technologies for novel product development.
Average Trading Volume: 97,842
Technical Sentiment Signal: Buy
Current Market Cap: £45.09M
For detailed information about HEMO stock, go to TipRanks’ Stock Analysis page.